Adverum Biotechnologies (ADVM)

• Market cap: $79.7M
• 1 day: -12.36%
• 5 days: -20.87%
• 1 month: -7.93%
• 3 months: -20.21%
• 6 months: -41.88%
• Year to date: -20.21%
• 1 year: -72.43%
• 5 years: -95.62%
• 10 years: -99.02%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Employees: 121

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

11% less funds holding

Funds holding: 76 [Q3] → 68 (-8) [Q4]

11.57% less ownership

Funds ownership: 81.49% [Q3] → 69.92% (-11.57%) [Q4]

27% less call options, than puts

Call options by funds: $45K | Put options by funds: $62K

44% less capital invested

Capital invested by funds: $120M [Q3] → $67.9M (-$52.3M) [Q4]

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16